Genetic polymorphisms may partly explain the inter-individual variability in susceptibility to cardiovascular disease and response to pharmacological treatments.
Answers are grounded in this paper and cite their sources.
May support genotype-guided cardiovascular pharmacotherapy; leaves open prospective validation before clinical adoption.
B2 Adrenergic Receptor Polymorphisms and Treatment- Outcomes in Cardiovascular Diseases Cardiovascular diseases (CVD) represent the major health problem in the western world and heavy social and economic burden. Under this name an eterogenous group of multifactorial conditions is included. There is appreciable inter-individual variability in the susceptibility to cardiovascular disease and in the response to the associated pharmacological treatments. Genetic polymorphism may be, at least in part, responsible for both susceptibility to disease and inter-individual variability in response to pharmacological treatments.
No takes yet. Share an insight, caveat, or question.
Cipolletta et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: